Business
Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials
Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials Canad...
About this update from Arch Biopartners, Inc.
[{"type":"text","content":"\n\n\n\nArch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Sept. 26, 2018\n\n\n\nTORONTO, Sept. 26, 2018  /CNW/ - Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH) (OTCQB: ACHFF) today announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for Metablok, the Company's lead drug candidate for preventing acute kidney injury.\nOver the next six to eight weeks Dalton will be completing the quality control process which will culminate with the release of a clinical drug product to be used in a phase I safety trial for Metablok.\nArch awaits the completion of ongoing toxicology and pharmacology studies at Nucro-Technics in November before confirming the start date of the phase I human trial. \nArch is currently finalizing the planning of the Phase I trial including the selection of a clinical site. Arch plans to make further disclosures when such details are confirmed.\nCardiac Surgery-Associated Acute Kidney Injury  \nAcute kidney injury (AKI) occurs in approximately 30% of patients that undergo cardiac bypass surgery with 1% of patients requiring dialysis. Currently, no specific therapies exist to prevent AKI. Worldwide, there are over one million patients per year that have cardiac surgery procedures.  \nAKI represents an additional challenge in patients recovering from cardiac surgery as they have higher incidences of mortality, complications in treatment course, and higher risk of complications such as cardiovascular events and infection. Of the patients that require dialysis because of cardiac surgery-associated AKI, many will require lifelong dialysis which increases overall morbidity and mortality. \nInflammation is known to contribute to AKI related to ischemia-reperfusion and other insults to the kidney that may occur in the course of cardiac surgery.  Metablok is a novel therapeutic agent that may protect the kidneys and p...